This trend describes the accelerating fusion of the traditionally separate Medical Technology (MedTech) sector (devices, diagnostics, software, wearables) with the Biopharmaceutical sector (drugs, biologics). Driven by Digital Health and Precision Medicine, this convergence manifests in several ways:
1) Companion Diagnostics—molecular tests (often liquid biopsies) required to identify patients who will benefit from a specific drug;
2) Digital Therapeutics (DTx)—software applications that deliver a therapeutic intervention alongside or instead of a drug; and
3) Smart Drug Delivery Systems—implantable sensors or connected devices that monitor a patient’s status and automatically adjust drug dosing.
This seamless integration is vital for the success of advanced therapies like cell and gene therapies, which require sophisticated cold-chain logistics, real-time remote monitoring (via DCTs), and highly precise diagnostic tools to ensure both safety and efficacy, creating integrated solutions that treat disease more holistically.
